Plain-English translation of NCT07538804 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage clinical trial testing , a new oral medication designed for patients with advanced lung cancer that has specific genetic changes called EGFR mutations. Researchers want to understand how safe this medication is, how your body processes it, and whether it can help shrink tumors. This is the first time this drug is being tested in humans.
Many patients with EGFR-mutated lung cancer eventually stop responding to existing treatments, so doctors need new options. This trial is exploring whether this medication could offer hope to people whose cancer has become resistant to current therapies.
You likely qualify if…
You likely don't qualify if…
You would take capsules of the medication by mouth as directed by the research team. Throughout the trial, you would have regular visits for blood tests, scans to monitor your tumor, and check-ins about any side effects you experience. The research team will carefully track how your body responds to the medication and adjust your dose if needed to find the safest and most effective level.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States
China